6 The phosphodiesterase-5 inhibitor sildenafil is certified for PAH in FC I–IV from the United states and FC II–III in Europe. Endothelin receptor antagonists (ERAs) including bosentan, sitaxentan and ambrisentan are oral therapies certified for use in PAH. As no oral agent has revealed superiority there stays debate as to which must be utilize